Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study

Oncology Reports

Volumn 15, Issue 5, 2006, Pages 1345-1350

  Ficorella, Corrado ^a   Ricevuto, E ^a   Morelli, M F ^a   Morese, R ^a   Cannita, K ^a   Cianci, G ^a   Porzio, G ^a   Di Rocco, Z C ^a   De Galitiis, F ^a   De Tursi, M ^b   Tinari, N ^b   Iacobelli, S ^b   Marchetti, P ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

5 fluorouracil; Advanced colorectal cancer; Irinotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; IRINOTECAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TIME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TIME FACTORS;

EID: 33744989481     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.5.1345     Document Type: Article

References (26)

1. Meta-Analysis Group in Cancer: Efficacy of intravenous continous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308, 1998.
2. Kohne CH, Schoffski P, Wilke H, et al: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16: 418-426, 1998. (Pubitemid 28135582)
3. Sobrero A, Aschele C and Bertino JR: Fluorouracil in colorectal cancer: a tale of two drugs-implications for biochemical modulation. J Clin Oncol 15: 368-381, 1997. (Pubitemid 27020595)
4. Meta-Analysis Group in Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16: 3537-3541, 1998.
5. Mayer RJ: Moving beyond fluorouracil for colorectal cancer. N Engl J Med 28: 963-964, 2000.
6. Machover D: A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 80: 1179-1187, 1997.
7. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709-715, 1996. (Pubitemid 26085513)
8. Rougier P, Bugat R, Douillard JY, et al : Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260, 1997. (Pubitemid 27020581)
9. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998. (Pubitemid 28510874)
10. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998. (Pubitemid 28510873)
11. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colrectal cancer: clinical overview. J Clin Oncol 19: 1501-1518, 2001. (Pubitemid 32202559)
12. Douillard JY, Cunningham D, Roth AD, et al : Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
13. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
14. Vanhoefer U, Harstrick A, Kohne CH, et al: Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 17: 907-913, 1999. (Pubitemid 29109322)
15. Sobrero A, Kerr D, Glimelius B, et al: New direction in the treatment of colorectal cancer: a look to the future. Eur J Cancer 36: 559-566, 2000. (Pubitemid 30156840)
16. Lévi F: Chronopharmacology of anticancer agents. In Handbook of Experimental Pharmacology: Physiology and Pharmacology of Biological Rhythms-Cancer Chemotherapy. Redfern PH and Lemmer B (eds). Springer-Verlag, Berlin, pp299-301, 1997.
17. Harris BE, Song R, Soong SJ and Diasio RB: Relationship between dihydropyrimidine dehidrogenase activity and plasma 5-fluorouracil levels with evidence for circadian varation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990. (Pubitemid 20030018)
18. Smaaland R, Abrahamsen JF, Svardal AM, et al : DNA cell cycle distrubution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients. Br J Cancer 66: 39-45, 1992.
19. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147, 1997. (Pubitemid 27337928)
20. Kakolyris S, Souglakos J, Kouroussis C, et al: A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer. Oncology 60: 207-213, 2001. (Pubitemid 32424525)
21. Ducreux M, Ychou M, Seitz JF, et al: Irinotecan combined with bolus fluorouracil, continuous infusion fluourouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 17: 2901-2908, 1999. (Pubitemid 29415251)
22. Falcone A, Di Paolo A, Masi G, et al : Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotheraphy-naive metastatic colorectal cancer patients. J Clin Oncol 19: 3456-3462, 2001. (Pubitemid 32730081)
23. Garufi C, Dogliotti L, D'Attino RM, et al : Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma. A phase I study. Cancer 91: 712-720, 2001. (Pubitemid 32173295)
24. Vamvakas L, Kakolyris S, Kouroussis C, et al : Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer. A multicenter phase II study. Am J Clin Oncol 25: 65-70, 2002. (Pubitemid 34131032)
25. O'Dwyer PJ, Manola J, Valone FH, et al: Fluorouracil modulation in colorectal cancer: lack of improvement with N-phospho-noacetyl-1-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule. An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 19: 2413-2421, 2001. (Pubitemid 32391212)
26. Leichman CG, Fleming TR, Muggia FM, et al: A phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13: 1303-1311, 1995.